TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.
Jiangsu Recbio Technology Co., Ltd. has entered into a product licensing agreement with India’s Biological E Company for its recombinant HPV 9-valent vaccine, REC603. This agreement allows Biological E to develop, manufacture, and commercialize the vaccine in India and markets led by UNICEF and PAHO, marking a significant step for Jiangsu Recbio in expanding its international market presence. The collaboration leverages Biological E’s extensive experience in vaccine R&D and commercialization, potentially enhancing the availability of the vaccine in high-demand regions, given India’s large population and the global need for effective HPV vaccines.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a Chinese joint stock company focused on biotechnology, particularly in vaccine development. The company is known for its recombinant HPV 9-valent vaccine, REC603, which is in the critical follow-up phase of Phase III clinical trials in China.
Average Trading Volume: 155,670
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$3.81B
See more insights into 2179 stock on TipRanks’ Stock Analysis page.